title: [Relevance of chemoprevention from PCPT trial].
abstract: Chemoprevention involves the active use of a drug inhibiting carcinogenesis in order to prevent the development of cancer. Prostate cancer has a high prevalence, long latent period and screening is inadequate. The morbidity and mortality of prostate cancer are significant, making it a good candidate for chemoprevention. Finasteride meets most of the necessary criteria for a chemoprevention agent. Nevertheless, some further information still needs to be obtained before considering its use in practice: the real nature of the increase in Gleason score, envisaged health savings, side effects on sexuality, impact on patient survival and the ideal target population.
authors.affiliation: Service d'Urologie de l'Hôpital La Milletrie, Université Poitiers, CHU Poitiers, France. j.irani@chu-poitiers.fr
authors.forename: J
authors.initials: J
authors.lastname: Irani
mesh_terms: D018890:Chemoprevention; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride